Roivant Sciences is set to report results for the fourth quarter and fiscal year ended March 31, 2026. Analysts expect continued focus on clinical progress across the company’s pipeline of biopharmaceutical assets.

Shares of GENB are declining approximately 13.00% on Monday, May 18, 2026, falling from a Friday, May 15 close of $16.00 to approximately $13.92 — a sharp selloff at precisely the stock's IPO price of $16.00, where technical and psychological resistance triggered profit-taking from investors who had been holding since the biotech's February 27, 2026 Nasdaq debut and are now exiting at breakeven levels.

Shares of REGN are trading down approximately 12% in Monday's session following a late-Friday clinical trial disclosure. The primary catalyst is the failure of fianlimab, Regeneron's experimental LAG-3 inhibitor, in a pivotal Phase 3 trial for first-line unresectable or metastatic melanoma.

Quarterly revenue remained at $0, reflecting a pre‑commercial stage company. Net loss expanded to $79.2 million (‑$0.52 per ADS), driven by higher R&D expense.

Recursion Pharmaceuticals reported Q1 2026 revenue of $6.47 million, missing estimates, with a net loss of $117.5 million but cash reserves of $665.2 million extending runway into early 2028. Clinical advancements include positive early data for REC-1245 (no dose-limiting toxicities) and REC-4881 (polyp reductions in familial adenomatous polyposis), alongside first dosing in REC-4539.

RGNX shares are down approximately 22% in premarket trading on May 14, 2026, despite the company announcing positive topline results from the pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202 for Duchenne muscular dystrophy. Primary catalyst: Q1 2026 revenue collapsed to $6.4 million from $89.0 million in Q1 2025 — a 93% year-over-year decline — driven by the expiration of ZOLGENSMA® patent royalties and the absence of the $70 million Nippon Shinyaku milestone recognized in Q1 2025.

Shares of CAI are declining approximately 14.00% on Wednesday, May 13, 2026, falling from a Tuesday, May 12 close of $18.87 to approximately $16.23 — extending a severe post-earnings selloff wave that has erased more than 30% of CAI's value year-to-date and reflects a persistent valuation compression driven by a cascade of institutional analyst price target reductions that began following the company's Q1 2026 earnings release.

BCAX shares are trading approximately 11% lower in Monday premarket activity, with shares indicated near ~$20.10, compared to Friday's closing price of $22.58. The primary catalyst is Bicara Therapeutics' Q1 2026 earnings report, released before the market opened on May 11, 2026, which revealed a widening net loss of $56.2 million.

Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% year-over-year from $2.77 billion, driven by cystic fibrosis (CF) franchise strength. Non-GAAP diluted EPS (earnings per share) came in at $4.47, surpassing consensus estimates around $4.23-$4.43; GAAP EPS was $4.02.

MapLight Therapeutics ( MPLT ) shares are down 10.59% at $27.44 in today's trading session. Intraday low hit $28.06 amid elevated volatility following recent positive trial news.

Nanobiotix S.A. (NBTX) shares plunged 11.18% to $31.20 during today's trading session from the previous close of $35.12. No specific company news or catalyst triggered the decline; the move appears driven by technical factors and high volatility. Trading volume reached approximately 154,000 shares, elevated compared to the average of around 60,000-70,000.

Analysts expect Q1 2026 revenue of $3.00 billion, up 8% from $2.77 billion in the year-ago quarter. Consensus earnings per share (EPS) estimate stands at $4.31, reflecting steady profitability from the cystic fibrosis (CF) portfolio.

Revolution Medicines (RVMD) stock surged +41% over the past 30 days, primarily driven by positive topline results from a pancreatic cancer trial announced mid-period. The stock experienced high volatility with a sharp spike followed by consolidation, reflecting investor enthusiasm for clinical progress.

CBIO shares plunged 29.3% to $15.81 from the previous close of $22.37 during today's trading session. Primary catalyst: Profit-taking and digestion of Q1 earnings reported on April 29, which showed an EPS loss of $0.70 beating consensus estimates of -$0.79 but highlighted ongoing cash burn despite a strong $189.2 million cash position.

SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66. The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.

Analysts expect Q1 2026 revenue of around $224 million, a significant increase from $108 million in Q1 2025. Consensus EPS forecast points to a loss of approximately $2.29 per share, potentially improved from prior quarters.

Shares of Regeneron Pharmaceuticals (REGN) are down approximately 6% on Wednesday, trading near $688 after closing at $731.77 on April 28, in an earnings-driven selloff despite a headline beat on both EPS and revenue. Primary catalyst: A sharp "beat and sell" market reaction driven by the continued deterioration of the core EYLEA franchise — total U.S. EYLEA HD and EYLEA net sales declined 10% year-over-year to $941 million, more than offsetting record Dupixent growth.

ERAS shares are down approximately 47.26% in Tuesday's session, falling from a prior close of $19.15 to approximately $10.10 intraday. The primary catalyst is the disclosure of a treatment-related patient death buried within the otherwise positively framed preliminary Phase 1 data release for lead drug candidate ERAS-0015.

CMPX shares are plunging approximately 62% in Monday's session, collapsing to roughly $1.98 from a prior close of $5.21 on April 24, 2026. The primary catalyst is the presentation of topline secondary endpoint data from the Phase 2/3 COMPANION-002 trial of tovecimig (CTX-009) plus paclitaxel in advanced biliary tract cancer, widely interpreted as disappointing.

Shares experienced a sharp decline of over 50% following interim Phase 1 data for obesity drug WVE-007, as results underwhelmed versus high expectations. Analysts retain a Strong Buy consensus with an average price target near $28, implying substantial upside potential.